Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3950572 | 0.81 | HDAC3 (0.45) | ALDH1A1KMT2AKCNH3POLBTDP1 | |
| SCHEMBL14446455 | 0.81 | KMT2A (0.38) | ALDH1A1KMT2AKCNH3KDM4EPOLB | |
| SCHEMBL632065 | 0.81 | HDAC3 (0.45) | ALDH1A1KMT2AKCNH3POLBTDP1 | |
| SCHEMBL631776 | 0.79 | KCNH3 (0.64) | ALDH1A1KMT2AKCNH3POLBTDP1 | |
| Hydrochloric Acid SCHEMBL2249099 | 0.77 | KCNH3 (0.67) | ALDH1A1KMT2AKCNH3POLBTDP1 | |
| SCHEMBL26547659 | 0.77 | KCNH3 (0.43) | ALDH1A1KMT2AKCNH3CYP1A1CYP1B1 | |
| SCHEMBL633443 | 0.76 | ALDH1A1 (0.60) | ALDH1A1KMT2AKCNH3KDM4EPOLB | |
| SCHEMBL10024341 | 0.76 | TDP1 (0.55) | ALDH1A1KMT2AKCNH3POLBTDP1 | |
| SCHEMBL4421097 | 0.76 | KMT2A (0.56) | ALDH1A1KMT2AKDM4EPOLBNPC1 | |
| SCHEMBL4421101 | 0.76 | KMT2A (0.56) | ALDH1A1KMT2AKDM4EPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229649-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190343837-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2019-11-14 | — | — | US | disclosed |
| US-10363254-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
| US-20160096819-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF | BASF SE (DE) | 2016-04-07 | — | — | US | disclosed |
| EP-2997020-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF | BASF SE (DE) | 2016-03-23 | — | — | EP | disclosed |
| CN-105189477-A | Process for preparing n-substituted 1h-pyrazole-5-carboxylic acid compounds and derivatives thereof | BASF SE | 2015-12-23 | — | — | CN | disclosed |
| WO-2014184343-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF | BASF SE (DE) | 2014-11-20 | — | — | WO | disclosed |
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. | 2012-12-06 | — | — | US | disclosed |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229649-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | CLPP, SI, SAMHD1 | ALDH1A1 1257/4885KMT2A 3111/4885KCNH3 957/4885 |
| US-20190343837-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | ALDH1A1 1257/4885KMT2A 3111/4885KCNH3 957/4885 |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | ALDH1A1 1257/4885KMT2A 3111/4885KCNH3 957/4885 |
| US-10363254-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | CLPP, SI, SAMHD1 | ALDH1A1 1257/4885KMT2A 3111/4885KCNH3 957/4885 |
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | JAK2, JAK1, JAK3 | ALDH1A1 1671/4885KMT2A 521/4885KCNH3 1636/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | ALDH1A1 1055/4885KMT2A 700/4885KCNH3 3015/4885 |
| US-20160096819-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF | CA3, CA2, CA1 | ALDH1A1 989/4885KMT2A 507/4885KCNH3 85/4885 |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 2606/4885KMT2A 3846/4885KCNH3 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.